NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Epigenic Therapeutics

Epigenic Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://www.epigenictx.com/

Last Round

Series B

Sep 7, 2025

Total Funding Raised

$112M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Epigenic Therapeutics is a biotechnology company that develops gene-silencing therapies using epigenome regulation and gene editing technology to treat chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

epigenetic medicinegene regulationepigenome editingepigenetic therapygene expression modulationepigenetic drugsCRISPRepigenetic editinglipid nanoparticleLNP deliverynon-permanent gene editingnext-gen gene therapybiotech drug discoveryepigenetic platformepigenetic therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epigenic Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Epigenic Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Epigenic Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 7, 2025
Series AAug 30, 2023
SeedAug 7, 2022

Key People

Founding team and executive leadership

Bob Zhang

CEO, Co-founder

Founding Team

Xinyu Huang

COO Head Of CMC

Executive Team

Epigenic Therapeutics Investors

Notable investors and investment history

Epigenic Therapeutics investors
InvestorRounds
FountainBridge CapitalSeed
Lapam CapitalSeries B
Tigeryeah CapitalSeed
OrbiMedSeries B, Series A
Trinity Innovation FundSeed
5Y CapitalSeed, Series A
Qiming Venture PartnersSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 7, 2025

    $60M round completed.

Epigenic Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Epigenic Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Epigenic Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range17
Year Founded2021
Last FundingSep 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.